Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Korea Moves To Help Samsung Electronics Create Consortium in Biosimilars

This article was originally published in PharmAsia News

Executive Summary

SEOUL - As the South Korean government accelerates its drive to get local producers of biosimilars globally competitive, the Ministry of Knowledge Economy is setting the stage for Samsung Electronics to become a giant in the emerging biosimlars market

You may also be interested in...



South Korea To Strengthen Medical Equipment Sector

SEOUL - Ahead of the July 2011 launch of Korea-EU free trade agreement, which local observers fear could damage the local healthcare sector, the Korean government is hammering out a set of measures to help the country's medical equipment industry

South Korea To Strengthen Medical Equipment Sector

SEOUL - Ahead of the July 2011 launch of Korea-EU free trade agreement, which local observers fear could damage the local healthcare sector, the Korean government is hammering out a set of measures to help the country's medical equipment industry

Korean Government Shifts Attention To CRO Sector In Steady Drive To Build Up Biotech Infrastructure, Biosimilars

SEOUL - After realizing that it was a late comer, the Korean government is now moving to strengthen its local CRO industry to support a clinical trial infrastructure that is bursting at the seams as MNCs flock to Korea to conduct early-stage trials

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC072167

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel